Cosmo Pharmaceuticals N.V.

SWX:COPN 株式レポート

時価総額:CHF 993.2m

Cosmo Pharmaceuticals 過去の業績

過去 基準チェック /56

Cosmo Pharmaceuticalsは、平均年間63%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間13.1% 20.5%収益成長率で 成長しています。 Cosmo Pharmaceuticalsの自己資本利益率は13.8%であり、純利益率は37.5%です。

主要情報

63.0%

収益成長率

64.3%

EPS成長率

Pharmaceuticals 業界の成長16.3%
収益成長率20.5%
株主資本利益率13.8%
ネット・マージン37.5%
前回の決算情報30 Jun 2024

最近の業績更新

Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture

Mar 28
Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture

Recent updates

Cosmo Pharmaceuticals N.V.'s (VTX:COPN) P/S Still Appears To Be Reasonable

Nov 22
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) P/S Still Appears To Be Reasonable

Market Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues

May 02
Market Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues

Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture

Mar 28
Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture

Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher

Mar 26
Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher

Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear

Dec 01
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear

Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 29
Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt

Nov 24
We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt

Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals

Mar 31
Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals

These 4 Measures Indicate That Cosmo Pharmaceuticals (VTX:COPN) Is Using Debt Reasonably Well

Aug 02
These 4 Measures Indicate That Cosmo Pharmaceuticals (VTX:COPN) Is Using Debt Reasonably Well

Increases to CEO Compensation Might Be Put On Hold For Now at Cosmo Pharmaceuticals N.V. (VTX:COPN)

May 20
Increases to CEO Compensation Might Be Put On Hold For Now at Cosmo Pharmaceuticals N.V. (VTX:COPN)

Cosmo Pharmaceuticals (VTX:COPN) Seems To Use Debt Quite Sensibly

Apr 03
Cosmo Pharmaceuticals (VTX:COPN) Seems To Use Debt Quite Sensibly

When Can We Expect A Profit From Cosmo Pharmaceuticals N.V. (VTX:COPN)?

Mar 07
When Can We Expect A Profit From Cosmo Pharmaceuticals N.V. (VTX:COPN)?

収支内訳

Cosmo Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

SWX:COPN 収益、費用、利益 ( )EUR Millions
日付収益収益G+A経費研究開発費
30 Jun 24185703720
31 Mar 24139323419
31 Dec 2393-53118
30 Sep 239932517
30 Jun 23104112016
31 Mar 23103142016
31 Dec 22102172015
30 Sep 2290261613
30 Jun 2278351311
31 Mar 2272281211
31 Dec 2165221111
30 Sep 216461413
30 Jun 2163-111714
31 Mar 2162-91814
31 Dec 2061-81914
30 Sep 2064-72114
30 Jun 2067-72415
31 Mar 2065-163015
31 Dec 1962-243515
30 Sep 1956-283914
30 Jun 1950-314214
31 Mar 1958-244612
31 Dec 1866-185110
30 Sep 1869-205210
30 Jun 1873-23549
31 Mar 1870-28509
31 Dec 1768-32469
30 Sep 1768-18389
30 Jun 1769-4319
31 Mar 17698238
31 Dec 166819167
30 Sep 1670181310
30 Jun 1672161013
31 Mar 16661321618
31 Dec 15612482323
30 Sep 15602412623
30 Jun 15592342923
31 Mar 15691542321
31 Dec 1480731719
30 Sep 1476781420
30 Jun 1472821021
31 Mar 146575919
31 Dec 135769818

質の高い収益: COPNは 高品質の収益 を持っています。

利益率の向上: COPNの現在の純利益率 (37.5%)は、昨年(10.4%)よりも高くなっています。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: COPN過去 5 年間で収益を上げており、収益は年間63%増加しています。

成長の加速: COPNの過去 1 年間の収益成長率 ( 541.8% ) は、5 年間の平均 ( 年間63%を上回っています。

収益対業界: COPNの過去 1 年間の収益成長率 ( 541.8% ) はPharmaceuticals業界10.2%を上回りました。


株主資本利益率

高いROE: COPNの 自己資本利益率 ( 13.8% ) は 低い とみなされます。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘